Which of the following antifungal drug is developing drug resistance and has not been prescribed for tinea cruris and tinea corporis for the last 2 years?

(a) Griseofulvin,Ref: Katzung, 13th ed., pg. 832 and class="katex">PMC4804599/* Among various options, topical terbinafine for 4 weeks appears to be the treatment of choice for limited disease (tinea corporis/cruris/pedis). For more extensive disease, the choice is less clear. It is also effective orally. Both terbinafine (250-500 mg/day for 2-6 weeks) and itraconazole (100--200 mg/day for 2-4 weeks) appear to be effective. Voriconazole is also an effective drug for these conditions.* Griseofulvin is an oral drug used for tinea infections. It is not effective topically. Because of emergence of resistance over the past few years, griseofulvin has been largely replaced by other antifungal agents like terbinafine and itraconazole.* Luliconazole is an imidazole topical cream recently approved by the FDA and the CDSCO for treatment of interdigital tinea pedis, tinea cruris, and tinea corporis.